X4 Pharmaceuticals Files 8-K

Ticker: XFOR · Form: 8-K · Filed: May 22, 2024 · CIK: 1501697

X4 Pharmaceuticals, Inc 8-K Filing Summary
FieldDetail
CompanyX4 Pharmaceuticals, Inc (XFOR)
Form Type8-K
Filed DateMay 22, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

X4 Pharma filed an 8-K, mostly standard disclosures.

AI Summary

X4 Pharmaceuticals, Inc. filed an 8-K on May 22, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statements and exhibits, as well as a Regulation FD disclosure. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that X4 Pharmaceuticals is making disclosures to the SEC, which could relate to ongoing business operations or regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

  • X4 Pharmaceuticals, Inc. (company) — Registrant
  • May 22, 2024 (date) — Date of earliest event reported
  • 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (address) — Principal executive offices
  • Arsanis, Inc. (company) — Former company name

FAQ

What is the primary purpose of this 8-K filing for X4 Pharmaceuticals?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as of May 22, 2024.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 22, 2024.

What is the principal executive office address for X4 Pharmaceuticals?

The principal executive office address for X4 Pharmaceuticals is 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.

What was X4 Pharmaceuticals' former company name?

X4 Pharmaceuticals' former company name was Arsanis, Inc.

Under which state was X4 Pharmaceuticals incorporated?

X4 Pharmaceuticals was incorporated in Delaware.

Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-05-22 08:09:57

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share XFOR The Nasdaq Stock Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that X4 Pharmaceuticals, Inc. (the "Company") may use from time to time in presentations or discussions with investors, analysts, and other parties. The information furnished under this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Corporate Presentation, dated May 22, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC. Date: May 22, 2024 By: /s/ Adam Mostafa Adam Mostafa Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.